The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-{2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl]-2,7-diazaspiro[3.5]nonan-7-yl}-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-{2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl]-2,7-diazaspiro[3.5]nonan-7-yl}-2-(2-methylimidazo[2,1-b]thiazol-6-yl) ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure. Both compounds underwent oxidative metabolism in NADPH-and glutathione-supplemented human liver microsomes to yield glutathione conjugates, which was consistent with their bioactivation to reactive species. Mass spectral fragmentation and NMR analysis indicated that the site of attachment of the glutathionyl moiety in the thiol conjugates was on the thiazole ring within the bicycle. Two glutathione conjugates were discerned with the imidazo[2,1-b]thiazole derivative 1. One adduct was derived from the Michael addition of glutathione to a putative S-oxide metabolite of 1, whereas, the second adduct was formed via the reaction of a second glutathione molecule with the initial glutathione-S-oxide adduct. In the case of the 2-methylimidazo[2,1-b]thiazole analog 2, glutathione conjugation occurred via an oxidative desulfation mechanism, possibly involving thiazole ring epoxidation as the rate-limiting step. Additional insights into the mechanism were obtained via 18 O exchange and trapping studies with potassium cyanide. The mechanistic insights into the bioactivation pathways of 1 and 2 allowed the deployment of a rational chemical intervention strategy that involved replacement of the thiazole ring with a 1,2,4-thiadiazole group to yield 2-
Introduction
Ghrelin is a 28-amino acid hunger-stimulating peptide that is produced in the stomach, pancreas, and hypothalamus (Kojima et al., 1999; Inui et al., 2004) . Ghrelin is a ligand for the growth hormone secretagogue receptor type 1a, a G-protein-coupled receptor expressed primarily in the pituitary gland, brain, and to a lesser extent in the periphery. Through its action on growth hormone secretagogue receptor type 1a, ghrelin exerts a variety of metabolic functions including stimulation of growth hormone release, stimulation of appetite and weight gain, and suppression of insulin secretion in rodents and humans (Nakazato et al., 2001; Wren et al., 2001; Dezaki et al., 2008; Cardona Cano et al., 2012; Heppner et al., 2012) . Thus, antagonizing growth hormone secretagogue receptor (GHSR)-1a with small molecule antagonists or inverse agonists is anticipated to improve glucose homeostasis and insulin sensitivity, while eliciting beneficial effects on body weight (Serby et al., 2006; Esler et al., 2007; Rudolph et al., 2007; Soares et al., 2008; Costantino and Barlocco, 2009) .
A recent report from our laboratory disclosed a proprietary series of spirocyclic piperidine-azetidine derivatives as potent and orally active inverse agonists of GHSR-1a . Structure-activity relationship studies revealed that analogs with distributed polarity in the form of the fused imidazo[2,1-b]thiazole acetamide and phenyl triazole functionalities (e.g., 1-{2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl]-2,7-diazaspiro[3.5]nonan-7-yl}-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-{2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl] 2,7-diazaspiro[3.5]nonan-7-yl}-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2) depicted in Fig. 1 ) demonstrated significant improvements in binding affinity (IC 50 , 10 nM) to the ghrelin receptor, while consistently displaying inverse agonism in a ghrelin functional assay. In addition, these structural changes also led to an improved pharmacokinetic profile (↓, clearance; ↑, oral bioavailability) in animals, which dx.doi.org/10.1124/dmd.113.051839. s This article has supplemental material available at dmd.aspetjournals.org.
ABBREVIATIONS: CID, collision-induced dissociation; compound 1, 1-{2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl]-2,7-diazaspiro[3.5]nonan-7-yl}-2-(imidazo [2,1-b] thiazol-6-yl)ethanone; compound 2, 1-{2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl]-2,7-diazaspiro[3.5]nonan-7-yl}-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone; compound 3, 1-{2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl]-2,7-diazaspiro[3.5]nonan-7-yl}-2-(2-methylimidazo [2, 1-b] [1, 3, 4] thiadiazol-6-yl)ethanone; DMSO-d 6 , dimethyl sulfoxide-d6; GHSR, growth hormone secretagogue receptor; GSH, reduced glutathione; HLM, human liver microsomes; HPLC, high-performance liquid chromatography; HSQC, multiplicity edited heteronuclear single quantum coherence; L-766,112, 5-[4-(methylsulfonyl) phenyl]-6-phenylimidazo [2,1-b] thiazole; LC-MS/MS, liquid chromatography-tandem mass spectrometry; m/z, mass-tocharge ratio; P450, cytochrome P450; TCI, triple resonance probe; TOCSY, total correlation spectroscopy, tR, retention time.
warranted a further examination of relevant preclinical safety endpoints as a prelude to candidate nomination.
From a drug metabolism perspective, the presence of the imidazo[2,1-b]thiazole scaffold in 1 and 2 raised a significant cause for concern, given the possibility of a cytochrome P450 (P450)-mediated S-oxidation on the thiazole sulfur (within the imidazo[2,1-b]thiazole framework) to yield an electrophilic S-oxide metabolite capable of reacting with proteins and/or the endogenous antioxidant glutathione (GSH). Indeed, the characterization of a GSH conjugate derived from Michael addition to an S-oxide metabolite of the imidazo [2,1-b] -766,112) (Fig. 1) provides precedence for this bioactivation pathway in liver microsomes (Thérien et al., 1997; Trimble et al., 1997) . Furthermore, a successful medicinal chemistry strategy involving internalization of the thiazole motif, resulting in the elimination of reactive metabolite liability of L-766,112, while retaining the primary pharmacology (selective inhibition of cyclooxygenase-2) has been presented in subsequent work ( Fig. 1) (Roy et al., 1997) . Other than thiazole-Soxidation, an additional bioactivation pathway can arise through thiazole ring scission (via the C4-C5 epoxidation → diol pathway) (Chatfield and Hunter, 1973; Mizutani et al., 1993; Yabuki et al., 1997; Yoon et al., 1998; Obach et al., 2008) . The corresponding thioamide metabolites, which are the by-products of thiazole ring cleavage, can undergo additional S-oxidation to electrophilic sulfenic acid derivatives (Dansette et al., 2005; Mansuy and Dansette, 2011) capable of oxidizing or forming mixed disulfide adducts with proteins or GSH and eliciting toxicity (Ziegler-Skylakakis et al., 1998; Hajovsky et al., 2012) .
In this report, we summarize our findings on the in vitro bioactivation of 1 and 2 in human liver microsomes (HLM) utilizing exogenously added nucleophiles to trap reactive species. In the case of the imidazo[2,1-b]thiazole derivative 1, two GSH adducts were formed. One adduct was derived from the addition of the thiol to a putative S-oxide metabolite of 1, whereas the formation of the second adduct involved the attachment of a second GSH molecule to the initial GSH-S-oxide adduct with concomitant liberation of the oxidized thiazole sulfur. With respect to the corresponding 2-methylimidazo[2,1-b]thiazole analog 2, GSH conjugation occurred via an oxidative desulfation mechanism, possibly involving thiazole ring epoxidation as the rate-limiting step. Characterization of the GSH conjugate structure and additional trapping studies with cyanide ion proved to be useful in deciphering the overall bioactivation mechanism associated with 2. The in vitro metabolism information was used to design the corresponding thiadiazole analog, 1-{2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl]-2,7-diazaspiro[3.5]nonan-7-yl}-2-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)ethanone analog 3 (see Fig. 1 ) that would be devoid of reactive metabolite formation. Indeed, 3 was resistant to bioactivation in HLM (inferred from the lack of GSH conjugate formation) while retaining inverse agonist potency for the ghrelin receptor and HLM stability noted with 1 and 2.
Materials and Methods
Materials. NADPH, GSH, and potassium cyanide were obtained from Sigma-Aldrich (St. Louis, MO). HLM were prepared from a mixed sex pool of 50 donors (provided by BD Biosciences, Woburn, MA). H 2 18 O (97%) and dimethyl sulfoxide (DMSO)-d 6 "100%" were obtained from Cambridge Isotope Laboratories Inc. (Andover, MA). All other commercially available reagents and solvents were of either analytical or high-performance liquid chromatography (HPLC) grade. The preparation of title compounds 1-3 is provided in the Supplemental Methods and Supplemental Fig. 1 .
Metabolite Identification and Reactive Metabolite Trapping Studies in HLM. Liver microsomal incubations were conducted at 37°C for 60 minutes in a shaking water bath. The incubation volume was 1.0 ml and consisted of 0.1 M potassium phosphate buffer (pH 7.4), MgCl 2 (3.3 mM), HLM (protein concentration = 1.0 mg/ml, P450 concentration = 0.5 mM), test compound (10 mM), and NADPH (1.3 mM). Additional microsomal incubations also included GSH (10 mM), N-acetylcysteine (10 mM), and/or potassium cyanide (5 mM) to trap reactive metabolites. Reactions were terminated by the addition of acetonitrile (3.0 ml). The solutions were centrifuged (3000g, 15 minutes), and the supernatants were transferred to clean 15-ml glass centrifuge tubes and concentrated to dryness. The residue was reconstituted with 200 ml 10% acetonitrile in water and analyzed for metabolite formation using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
18
O Incorporation Studies in HLM. For H 2
O studies, 15-ml glass centrifuge tubes containing 1.0 ml of 0.1 M phosphate buffer (pH 7.4) were concentrated to dryness using an evaporative centrifuge. H 2 18 O (840 ml, 97%) was added to the dried centrifuge containing phosphate buffer. Potassium phosphate (pH 7.4) buffered H 2
O was used to create 1.0-ml incubations containing 2 (10 mM) and 3.3 mM MgCl 2 (20 ml) in HLM (protein concentration = 1.0 mg/ml, P450 concentration = 0.5 mM). The isotopic enrichment of H 2 18 O was~89.7%. Identical incubations were also performed in the presence of GSH (10 mM). Samples were placed in a shaking water bath set to 37°C. After 60 minutes, the reactions were quenched with 3.0 ml of acetonitrile and centrifuged at 3000g for 5 minutes. The supernatants were transferred to clean 15-ml centrifuge tubes and concentrated to dryness. The samples were analyzed for 18 O incorporation by LC-MS/MS. LC-MS/MS Methodology for Metabolite Identification Studies. The HPLC system consisted of an Acella quaternary solvent delivery pump, an Accela autoinjector, and a Surveyor PDA Plus photodiode array detector (Thermo Electron Corporation, Waltham, MA). Chromatography was performed on a Phenomenex Hydro RP column (4 mm 4.6 mm Â 150 mm; Phenomenex, Torrance, CA). The mobile phase was composed of 5 mM ammonium formate buffer (pH = 3.0) (solvent A) and acetonitrile (solvent B). The flow rate was 1.0 ml/min. The LC gradient started at 10% B for 5 minutes, was ramped linearly to 50% B over 35 minutes, ramped linearly to 90% B over 10 minutes, returned to the initial condition over 1.0 minute, and allowed to equilibrate for 4.0 minutes. Post-column flow passed through the PDA detector to provide ultraviolet (l = 254 nm) detection prior to being split to the mass spectrometer such that mobile phase was introduced into the electrospray source at a rate of 100 ml/min. The LC system was interfaced to a Thermo Orbitrap mass spectrometer operating in positive ion electrospray mode. Xcalibur software, version 2.0, was used to control the HPLC/mass spectrometry system. Full scan data were collected at 15,000 resolution. Data dependent product ion scans of the two most intense ions found in the full scan were obtained at 15,000 resolution. The dynamic exclusion function was used with a 1.0-minute exclusion duration after three successive product ion scans with an early exclusion if the precursor ion falls below a signalto-noise ratio of 20.
Biosynthesis of GSH Conjugates. GSH conjugates M3-1 and M5-2 detected in the course of reactive metabolite trapping studies with 1 and 2 were biosynthesized from human liver microsomal incubations. Six incubations of 1 or 2 were carried out in 50-ml polypropylene centrifuge tubes at 37°C for 60 minutes in a shaking water bath. The incubation volume was 10 ml and consisted of 0.1 M potassium phosphate buffer (pH 7.4), MgCl 2 (3.3 mM), HLM (protein concentration = 1.0 mg/ml), test compound (60 mM), GSH (10 mM), and NADPH (1.3 mM). Reactions were terminated by the addition of acetonitrile (30 ml). The solutions were centrifuged (3000g, 15 minutes), and the supernatants were transferred to clean 50-ml polypropylene centrifuge tubes and concentrated to dryness. The residue in each tube was reconstituted with 400 ml 10% acetonitrile in water. The reconstituted samples were combined in a 2-ml HPLC vial and were placed onto an HPLC semipreparative system in eight 3-ml injections. This system consisted of a Shimadzu SiL-HTC autosampler, two LC-20AD solvent pumps, an SPD-M20A diode array detector, and a FRC-10 A fraction collector (Shimadzu USA, Columbia, MD). Separation was performed on a Zorbax RX C8, 9.4 Â 250 mm, 5-mM semipreparative HPLC column (Phenomenex). The mobile phase was composed of 0.1% formic acid (solvent A) and acetonitrile (solvent B). The flow rate was 4.0 ml/min. The LC gradient started at 10% B for 5 minutes, ramped linearly to 50% B over 35 minutes, ramped linearly to 90% B over 10 minutes, returned to the initial condition over 1.0 minutes, and allowed to equilibrate for 4.0 minutes. HPLC fractions were collected throughout the run at 1.0-minute intervals. Aliquots (100 ml) of fractions at the retention time (t R ) of the ultraviolet peak corresponding to the GSH conjugate (M3-1 or M5-2) were analyzed by liquid chromatography-mass spectrometry for verification. Fractions containing the peak were combined into a single 15-ml glass centrifuge tube and concentrated to dryness. In the case of M3-1, it was difficult to obtain a pure isolate because of poor chromatographic resolution between M3-1 and M2-1. Hence, a crude isolate of M3-1 was used in NMR characterization. The residues were evacuated in a drybox for~2 hours prior to reconstitution in DMSO-d 6 for NMR analysis.
NMR Analysis of Metabolites. NMR spectra for 1 and M3-1 were recorded on a Bruker Avance 600 MHz instrument (Bruker BioSpin Corporation, Billerica, MA) controlled by TOPSPIN V3.0 and equipped with a 1.7 mm cryotriple resonance probe (TCI). NMR spectra for 2 and M5-2 were recorded on a Bruker Avance 600 MHz instrument (Bruker BioSpin Corporation) controlled by TOPSPIN V2.1 and equipped with a 5 mm cryo-TCI probe. Synthetic samples and isolated materials were dissolved in 0.15 ml (5 mm TCI probe) or 0.05 ml (1.7 mm TCI probe) of DMSO-d 6 . All spectra were referenced using residual DMSO-d 6 (d = 2.49 ppm relative to tetramethylsilane, d = 0.00 for 1 H and d = 39.5 ppm relative to tetramethylsilane, d = 0.00 for 13 C). Onedimensional spectra were typically recorded using a sweep width of 8000 Hz and a total recycle time of approximately 7 seconds. The resulting timeaveraged free induction decays were transformed using an exponential line broadening of 1.0 Hz to enhance signal-to-noise ratio. The two-dimensional data [correlation spectroscopy, total correlation spectroscopy (TOCSY), multiplicity edited heteronuclear single quantum coherence (HSQC), and heteronuclear multiple bond correlation] were recorded using the standard pulse sequences provided by Bruker. A 1 K Â 128 data matrix was acquired using a minimum of 4 scans and 16 dummy scans. The data were zero-filled to a size of 1 K Â 1 K. A mixing time of 80 milliseconds was used in the TOCSY experiments.
Results
In Vitro Metabolism of Imidazo[2,1-b]thiazole Derivative 1 in HLM. In HLM supplemented with NADPH and GSH, three metabolites of 1 (denoted as M1-1, M2-1, and M3-1) were observed ( Fig. 2A) . Collision-induced dissociation (CID) spectra of 1 and its metabolites M1-1, M2-1, and M3-1 are shown in Figs. 3-5. In the case of 1 (t R = 18.82 minutes; MH + = 482.1524), the major fragment ions present at mass-to-charge ratio (m/z) 318. 1476, 301.1210, 262.1004, 192.0318, and 165 .0112 were consistent with the structure (see CID spectrum in Fig. 3A ). Metabolite M1-1 eluted at t R = 17.70 minutes and possessed MH + = 516.1579, which is an addition of 34.0055 Da to the molecular mass of 1 (Fig. 3B) . The presence of the fragment ions at m/z 318.1476 and 192.0318 in the CID spectrum of M1-1 indicated that the 2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl-2,7-diazaspiro[3,5]-nonane] portion was unaltered. A proposed structure of M1-1 that is consistent with the observed molecular weight and mass spectrum is shown in Fig. 3B .
Metabolites M2-1 (t R = 17.08 minutes) and M3-1 (t R = 16.47 minutes) possessed MH + at 1096.3200 and 805.2311 m/z, respectively. The CID spectra of M2-1 and M3-1 are shown in Figs. 4 and 5, respectively. M2-1 contained two molecules of GSH in its structure as evident from the facile loss of two pyroglutamic acid components (m/z 967.2753 and m/z 838.2335) in its CID spectrum. Furthermore, the presence of the fragment ion at m/z 318.1468 implied that the 2-[2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl-2,7-diazaspiro[3,5]-nonane] portion in M2-1 was unchanged. A structure of M2-1 that is compatible with the observed molecular weight and fragmentation pattern is shown in Fig. 4 , and a mechanistic hypothesis that rationalizes its formation is provided in Fig. 15 in the Discussion.
The molecular mass of M3-1 (MH + = 805.2312) suggested that the metabolite was derived from the addition of GSH to an oxidized metabolite of 1. The fragment ions at m/z 730.1973 and m/z 676.1872 in the CID spectrum of M3-1 were derived from the characteristic losses of the glycine (75 Da) and glutamic acid components (129 Da) of GSH (Baillie and Davis, 1993 2,3-triazol-2-yl)benzyl-2,7-diazaspiro[3,5]-nonane] scaffold in 1 was unmodified. On the basis of the fragmentation pattern, we inferred that oxidation and subsequent GSH conjugation had occurred on the imidazo[2,1-b]thiazole ring. There are two obvious pathways through which this can arise, either via a P450-mediated epoxidation at the C4-C5 position of the thiazole ring with addition of GSH or through a P450-mediated S-oxidation of the thiazole sulfur followed by addition of GSH to the S-oxide metabolite (structure depicted in Fig. 5 ), similar to one discerned with the imidazo[2,1-b]-thiazole derivative L-766,112 (Trimble et al., 1997) . To distinguish between the two possibilities, a H-13 C HSQC spectrum of M3-1 are more consistent with the structure resulting from the S-oxidation pathway and are also closely aligned with the NMR data reported for the GSH conjugate of L-766,112 S-oxide (Trimble et al., 1997) . Furthermore, the TOCSY data set (Fig. 6A) for the M3-1 isolate contains cross-peaks between the d 6.05 ppm and the d 3.56/4.65 ppm resonances, indicating a direct coupling between all of these protons. On the basis of these data the M3-1 isolate is tentatively assigned as the thiazole-S-oxide with a GSH molecule attached at the C3 position of the thiazole ring. This structure strongly infers that the route of formation of M3-1 is through a biotransformation step involving S-oxidation.
Bioactivation of
The potential for S-oxide formation was then specifically examined in NADPH-supplemented HLM incubations of 1 (10 mM) in the absence and presence of GSH (10 mM) (Fig. 7, A and B, respectively). Two monohydroxylated metabolites (MH + = 498.1473) designated as M4-1 (minor) and M5-1 (major) were observed in HLM incubations in the absence of GSH. The CID spectrum of the minor metabolite M4-1 is shown in Supplemental Fig. 2 . The detection of a fragment ion at m/z 334.1420 (addition of oxygen to m/z 318.1473) indicated that M4-1 was derived from a monohydroxylation on the spirocyclic-azetidine ring. In contrast, the CID spectrum of the major metabolite M5-1 (Fig. 8) contained fragment ions that suggested that the imidazo[2,1-b]thiazole motif was the site of oxidation. Furthermore, the fragment ion at m/z 452.1401 (MH + -SO) implied that M5-1 was the S-oxide metabolite of 1. Addition of GSH to the NADPHsupplemented HLM incubation of 1 significantly diminished the levels of M5-1 (Fig. 7B) , which is consistent with the adduction of M5-1 to GSH resulting in the formation of M3-1.
In Vitro Metabolism of 2-Methylmidazo[2,1-b]thiazole Derivative 2 in HLM. Figure 2B depicts an extracted ion chromatogram of an incubation mixture comprised of NADPH, GSH, and 2 conducted at 37°C for 60 minutes. A total of five metabolites was observed in a NADPH-dependent fashion. The 
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M2-2 elutes after 2 under the reversed phase HPLC conditions, we speculate that M2-2 is an N-oxide metabolite of 2 by inference to related tertiary basic amine drugs, such as loperamide, that undergo N-oxidation (Kalgutkar and Nguyen, 2004 (Fig. 9B) . Metabolite M4-2 (t R = 17.1 minutes) also possessed a MH + at 512.1630, consistent with a monohydroxylation in 2. In contrast with M1-2 and M2-2, metabolite M4-2 appeared to be derived from an A proposed structure for M4-2 that is compatible with the observed mass spectrum is shown in Supplemental Fig. 5 .
Metabolite M5-2 (t R = 15.89 minutes) possessed a MH + at 787.2747 and demonstrated a fragment ion at m/z 658.2308, which was consistent with the loss of a glutamic acid component (129 Da) of GSH (Fig. 10A ). This observation suggested that M5-2 was a GSH conjugate of 2. The presence of the fragment ion at m/z 318.1474 implied that the site of attachment of GSH was on the 2-methylimidazo[2,1-b]thiazole ring system. Furthermore, the fragment ion at m/z 514.1776 was assigned as a cleavage adjacent to the cysteinyl thioether moiety with charge retention on the imidazole residue. The occurrence of the fragment ion at m/z 514.1776 is consistent with the presence of an aromatic thioether motif in M5-2 (Baillie and Davis, 1993). A proposed structure for M5-2 that is consistent with its mass spectrum is shown in Fig. 10A . Replacement of GSH with N-acetylcysteine as a trapping agent in NADPH-supplemented HLM incubations of 2 led to the formation of M6-2 (t R = 18.2 minutes, MH + = 643.2212), an analogous conjugate of M5-2. The CID spectrum of M6-2 and interpretation of key fragment ions is depicted in Fig. 10B . As such, elucidation of the structure of the GSH conjugate (M5-2) was largely aided by the isolation of the thiol adduct from large-scale HLM incubations of 2 in the presence of NADPH and GSH, and subsequent characterization by NMR spectroscopy.
NMR Characteristics of GSH Conjugate M5-2. (Fig. 12) . In this data set there are correlations from both the new methylene resonance (d = 4.93 ppm) and the methyl resonance (d = 2.37 ppm) to a 13 C with a chemical shift of d = 201.7 ppm. A 13 C chemical shift in the range of 190-220 ppm is unique and indicates a carbonyl with no adjacent hetero-atom, either a ketone or aldehyde. A structure that satisfies all these data is shown in Fig. 10A , the biosynthetic pathway of which will be revealed in the Discussion.
18 O Incorporation Studies. The source of the carbonyl oxygen in GSH conjugate M5-2 was investigated in NADPH-and GSHsupplemented HLM incubations of 2 conducted in H 2 18 O. As expected, the diol metabolite M3-2 incorporated was not observed in the GSH adduct M5-2. This observation suggested that the source of the carbonyl oxygen in M5-2 is derived from molecular oxygen.
Trapping Studies with Potassium Cyanide. Attempts to trap the putative iminium ion intermediate involved in the formation of GSH conjugate M5-2 (see Discussion and Fig. 16 on the proposed mechanism for the formation of M5-2) were initiated in NADPHsupplemented HLM incubations of 2 in the presence of potassium cyanide (5 mM). Figure 14 indicates the CID spectrum of an adduct M7-2 (t R = 18.4 minutes, MH + = 539.1739) formed in these incubations in a NADPH-and cyanide-dependent fashion. The proposed structure of the cyano adduct M7-2 and corresponding fragment ions that led to the structural elucidation are also shown in Fig. 14. A mechanism for the formation of M7-2 is shown in Fig. 16 (see Discussion).
In Vitro Bioactivation of 2-Methylimidazo[2,1-b]thiadiazole Derivative 3 in Human Liver Microsomes. LC-MS/MS analysis of an incubation mixture of 3 in NADPH-and GSH-supplemented HLM did not reveal the presence of any GSH conjugates of 3, suggesting that 3 is devoid of the bioactivation liability associated with 1 and 2.
Comparison of the In Vitro Ghrelin Receptor Pharmacology and HLM Stability of Compounds 1-3. Potency against the ghrelin receptor was determined in the previously described GHSR-1a binding assay using [
125 I]ghrelin . As shown in Fig. 1 , the IC 50 values for 1, 2, and 3 were 8.0, 4.7, and 2.6 nM, respectively. The microsomal stability of compounds 1-3 (final concentration = 1 mM) was assessed by monitoring substrate consumption after incubation with HLM in the presence of NADPH cofactor for 30 minutes at 37°C. Microsomal half-lives, reflecting depletion of test compounds, were scaled to the corresponding intrinsic clearance values using the wellstirred model (Obach, 1999) . Under these experimental conditions, the half-lives of 1, 2, and 3 in HLM were 19.1, 28.6, and 38.8 minutes, which translated into intrinsic clearance values (ml/min/kg) of 48, 32, and 24, respectively.
Discussion
The otherwise attractive pharmacological and pharmacokinetic attributes of ghrelin inverse agonists 1 and 2 were offset by the presence of the imidazo[2,1-b]thiazole bicycle as part of the core structure, especially in light of previous studies by Trimble et al. (1997) who demonstrated the microsomal S-oxidation of the thiazole portion (within the bicycle) to an electrophilic sulfoxide metabolite that underwent a 1,4-Michael addition reaction with GSH. In addition, evidence linking thiazole ring bioactivation with preclinical (or clinical) toxicity has been presented for several thiazole-based xenobiotics and drugs (Kalgutkar et al., 2005) . For example, the clinical hepatotoxicity noted with the nonsteroidal anti-inflammatory drug sudoxicam (Supplemental Fig. 6 ) has been attributed to a metabolic process involving thiazole ring scission to a toxic thiourea metabolite (Obach et al., 2008) . The structurally related anti-inflammatory agent (and marketed drug) meloxicam does not possess the hepatotoxic liability associated with sudoxicam. Although introduction of a methyl group at the C5 position of the thiazole ring in meloxicam is the only structural difference, the change dramatically alters the metabolic profile such that oxidation of the C5 methyl group to the alcohol metabolite (see Supplemental Fig. 7) constitutes the principal metabolic (Chesné et al., 1998; Obach et al., 2008) .
Taking into consideration the above mentioned structure-toxicity relationship and the growing evidence linking immune-mediated drug toxicity with reactive metabolite formation (Park et al., 2011; Stepan et al., 2011; Sakatis et al., 2012; Thompson et al., 2012) , we decided to examine the bioactivation potential of 1 and 2 in HLM. Incubation of 1 and 2 in NADPH-and GSH-supplemented HLM led to the formation of reactive species that were trapped with GSH. Metabolism (including bioactivation) of both 1 and 2 was blocked when the HLM incubations were conducted in the presence of ketoconazole (a selective CYP34 inhibitor), which implicated a role for CYP3A4 in the metabolism of the two imidazo[2,1-b]thiazole derivatives. LC-MS/MS characterization of the GSH conjugates suggested that the site of bioactivation in both compounds was on the imidazo[2,1-b]thiazole bicycle. In the case of the imidazo[2,1-b]thiazole derivative 1, the formation of the diol metabolite M1-1 was consistent with a bioactivation pathway involving thiazole ring oxidation by P450 enzyme(s) at the (Fig. 15, pathway A ). An alternate pathway that leads to M3-1 involves P450-mediated oxidation on the thiazole sulfur to the S-oxide metabolite M5-1, followed by the Michael addition of GSH to yield adduct M3-1 (see Fig. 15 , pathway B) as outlined previously with the imidazo[2,1-b]thiazole analog L-766,112 (Trimble et al., 1997) . NMR analysis of the crude M3-1 isolate indicated that the GSH adduct was derived from addition of the thiol nucleophile to the electrophilic S-oxide M5-1 and not from the ring opening of epoxide 12. The hypothesis is further strengthened by the observation that addition of GSH to NADPH-supplemented HLM incubations of 1 significantly diminished the levels of M5-1 formed in the incubations. Reason(s) for the lack of formation of the GSH adduct 13 shown in Fig. 15 , pathway A, are not apparent from this analysis. It is possible that hydrolytic ring opening of 12 proceeds at a faster rate than the corresponding reaction with GSH. Apart from the mono-GSH adduct M3-1, we also noted the formation of a novel bis-GSH conjugate M2-1 with two molecules of GSH attached to the imidazo[2,1-b]thiazole framework. A plausible mechanism outlining the formation of M2-1 is presented in Fig. 15 (pathway C) and involves the initial addition of a GSH molecule to the putative S-oxide metabolite of 1 (i.e., M5-1) to generate M3-1 followed by addition of a second molecule of GSH across the electrondeficient C5 position on the imidazole ring system in M3-1, which results in imidazo[2,1-b]thiazole-S-oxide ring scission. The outlined mechanism is certainly not beyond the realm of possibilities, considering the well-known chemical (and glutathione transferase-mediated) displacement reaction of GSH with electron-deficient heteroaromatic rings (e.g., pyridine, pyrimidine, etc.) that contain alkylsulfoxide and/or alkylsulfone as leaving groups (Clapp, 1956; Colucci and Buyske, 1965; Conroy et al., 1984; Graham et al., 1989; Yang et al., 2012) . A literature example that bears much commonality to the present situation is evident with the proton pump inhibitor pantoprazole wherein the benzimidazole-2-sulfoxide motif undergoes nucleophilic attack by GSH at the electron-deficient C2 position on the benzimidazole ring (Zhong et al., 2005) . Certainly, one can view M5-1 (in Fig. 15 , pathway C) as an electron-deficient heterocycle (imidazole ring) with an excellent leaving group (alkylsulfoxide) at the C5 position, which is poised for nucleophilic displacement by GSH.
In the case of 2, LC-MS/MS data on the GSH and N-acetylcysteinyl conjugates M5-2 and M6-2, respectively, were also consistent with thiazole ring bioactivation. From a structure-activity relationship standpoint, the C-2 methyl group on the imidazo[2,1-b]thiazole ring in 2 did not prevent thiazole ring bioactivation to reactive metabolite(s), which contrasts the structure-toxicity relationship noted for sudoxicam and meloxicam. From a mechanistic perspective, we speculate that the rate-limiting step in the formation of M5-2 and M6-2 proceeds via a P450-mediated oxidation on the thiazole ring in 2 to generate epoxide 14, which upon hydrolysis would yield the diol metabolite M3-2 or undergo ring scission to an iminium species 15 (Fig. 16) . A twoelectron reduction of the iminium bond in 15, possibly mediated by GSH, would lead to the 2-mercaptoimidazole 16, which may be trapped by GSH or N-acetylcysteine via a developing ring-opened isothiocyanate 17 to afford sulfydryl conjugates M5-2 and M6-2, respectively. Overall the mechanistic possibility is compatible with the results of the 18 O labeling studies, wherein lack of incorporation of 18 O in M5-2 indicates that the source of the carbonyl oxygen in M5-2 is from molecular oxygen (i.e., from a P450-mediated oxidation).
To examine whether iminium species 15 is indeed formed as an intermediate in the pathway leading to M5-2, 2 was incubated in HLM in the presence of NADPH and excess potassium cyanide, which is typically used to trap electrophilic iminium ions generated via a twoelectron oxidation of amines (Rose and Castagnoli, 1983; Argoti et al., 2005) . The accurate mass of the metabolite M7-2 detected in these incubations was consistent with the addition of cyanide across 15, which provided additional support for our overall mechanistic hypothesis. One can rationalize the formation of M7-2 to occur via the initial addition of cyanide across the iminium bond in 15 to yield the cyano adduct 18, which upon cyclization would lead to M7-2 (see Fig. 16 ). With reference to the step involving the reduction of the iminium bond in 15 (to yield 2-mercaptoimidazole 16), we invoked the involvement of GSH as a reducing agent, because two-electron reduction of imines by GSH is a well precedented reaction. For example, N-acetyl-pbenzoquinone imine, the oxidation product of acetaminophen, can react with GSH in a 1,4-Michael fashion to yield a stable GSH adduct or undergo a two-electron reduction to the parent drug in the presence of the thiol (Rosen et al., 1984; Potter and Hinson, 1986) . In the present situation, we anticipate that the thioaminal conjugation product obtained through addition of GSH across the imine double bond in 15 will be highly unstable and spontaneously decompose back to 15. Clearly, a more rigorous experimental analysis of these individual mechanistic steps will be needed to fully validate our hypothesis on the oxidative metabolism/bioactivation of these unique bicyclo-heterocylic compounds. Toward this end, the imidazo[2,1-b]thiazole intermediates used in the synthesis of the title compounds 1 and 2 (see Supplemental Methods) could provide much utility in testing certain mechanistic hypotheses (e.g., the use of deuterium exchange to distinguish S-oxidation from mono-hydroxylation).
Overall, given this information, it appeared reasonable to attempt to eliminate bioactivation liability in 1 and 2 via small structural modifications of the thiazole ring that would preserve the physicochemical properties (e.g., molecular weight, lipophilicity) largely responsible for pharmacologic potency and HLM stability. Consequently, the 2-methylimidazo[2,1-b][1,3,4]thiadiazole analog 3 was synthesized to prevent thiazole ring epoxidation and/or addition of GSH to an S-oxide metabolite. An identical medicinal chemistry strategy had been successfully used to abrogate thiazole ring bioactivation with nonpeptidyl thrombopoietin receptor agonists containing the 2-aminothiazole motif (Kalgutkar et al., 2007) . As such, the absence of the GSH conjugate formation in NADPH-and GSH-supplemented HLM incubations with 3 indicates that the thiadiazole derivative is devoid of the reactive metabolite liability associated with 1 and 2 and demonstrates the success of this medicinal chemistry tactic. Compound 3 also retained the potent in vitro ghrelin inverse agonism and HLM stability characteristics discerned with lead compounds 1 and 2. In summary, we demonstrated the human liver microsomal bioactivation of the imidazo[2,1-b]thiazole functionality present as part of the core structure in novel ghrelin inverse agonists. Characterization of the GSH adducts using LC-MS/MS and NMR techniques provided indirect information on the structures of the reactive species, thereby providing insight into the bioactivation mechanism. The information gained from these studies was used to direct medicinal chemistry efforts in the design of a compound with the attractive pharmacology and disposition characteristics observed with the prototypes while avoiding potential safety concerns associated with the bioactivation of the imidazo[2,1-b]thiazole functionality. Additional lead optimization 
